Phase III trial of arterolane/piperaquine versus artemether/lumefantrine in patients aged ≥12 years with acute uncomplicated Plasmodium falciparum malaria

Trial Profile

Phase III trial of arterolane/piperaquine versus artemether/lumefantrine in patients aged ≥12 years with acute uncomplicated Plasmodium falciparum malaria

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Arterolane/piperaquine (Primary) ; Artemether/lumefantrine
  • Indications Falciparum malaria
  • Focus Registrational; Therapeutic Use
  • Sponsors Ranbaxy Laboratories
  • Most Recent Events

    • 20 Jan 2015 New trial record
    • 15 Dec 2014 Results published in Ranbaxy Laboratories media release.
    • 15 Dec 2014 Based on data from this trial, arterolane/piperaquine [Synriam] has been launched in seven African countries (Nigeria, Uganda, Senegal, Cameroon Guinea, Kenya and Ivory Coast), according to a Ranbaxy Laboratories media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top